Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S ("Stenocare") and its local partner have successfully secured approval for the reimbursement of the innovative ASTRUM 10-10 product by major German health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10.
The ASTRUM 10-10 oil product was made available to German patients in January 2025 and has now been approved for 100% reimbursement by two leading German health insurance providers, Techniker Krankenkasse and AOK Rheinland.
Germany represents the largest medical cannabis market in Europe. Industry analysts, including Prohibition Partners, forecast a 275% growth by 2027, with total sales expected to reach EUR 1 billion.
Stenocare's new and innovative medical cannabis oil product is officially named Astrum 10-10 Ext Stenocare. It contains 10 mg/ml of THC and 10 mg/ml of CBD, supplied in a 30 ml bottle. The PNZ is 15192488 and the German supplier is ADREXpharma GmbH.
The Stenocare Astrum product is based on advanced oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a common challenge in medicinal dosing by promoting the consistent absorption of active ingredients. Stenocare has conducted a successful pharmacokinetic (PK) study in dogs, which demonstrated two key improvements in the lymphatic system that can significantly enhance bioavailability: A significant increase in cannabinoid uptake into the bloodstream, improving therapeutic effect and a faster, more uniform absorption across patients.
Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/ to automatically receive the latest news and information about the company.